MX2021005764A - Composición farmacéutica que comprende inhibidores de poli (adenosina difosfato (adp)-ribosa) polimerasas (parp). - Google Patents

Composición farmacéutica que comprende inhibidores de poli (adenosina difosfato (adp)-ribosa) polimerasas (parp).

Info

Publication number
MX2021005764A
MX2021005764A MX2021005764A MX2021005764A MX2021005764A MX 2021005764 A MX2021005764 A MX 2021005764A MX 2021005764 A MX2021005764 A MX 2021005764A MX 2021005764 A MX2021005764 A MX 2021005764A MX 2021005764 A MX2021005764 A MX 2021005764A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
parp inhibitors
solid dispersion
preparation
carrier material
Prior art date
Application number
MX2021005764A
Other languages
English (en)
Inventor
Hao Chen
Xu Wang
Jiajia Xu
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2021005764A publication Critical patent/MX2021005764A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Una dispersión sólida para inhibidores de PARP, que comprende un compuesto representado por la Fórmula I y un material portador, en donde el material portador comprende polivinilpirrolidona; una composición farmacéutica que comprende una dispersión sólida, un relleno, un agente desintegrante y un lubricante; un método de preparación para la dispersión sólida; el uso de una dispersión sólida de la composición farmacéutica en la preparación de fármacos para tratar cánceres.
MX2021005764A 2018-11-16 2019-11-15 Composición farmacéutica que comprende inhibidores de poli (adenosina difosfato (adp)-ribosa) polimerasas (parp). MX2021005764A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811363490 2018-11-16
PCT/CN2019/118714 WO2020098774A1 (zh) 2018-11-16 2019-11-15 一种包含parp抑制剂的药物组合物

Publications (1)

Publication Number Publication Date
MX2021005764A true MX2021005764A (es) 2021-10-01

Family

ID=69600245

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005764A MX2021005764A (es) 2018-11-16 2019-11-15 Composición farmacéutica que comprende inhibidores de poli (adenosina difosfato (adp)-ribosa) polimerasas (parp).

Country Status (12)

Country Link
US (1) US20210393626A1 (es)
EP (1) EP3881846A4 (es)
JP (1) JP7469304B2 (es)
KR (1) KR20210092771A (es)
CN (3) CN115400087B (es)
AU (1) AU2019379706A1 (es)
BR (1) BR112021009190A2 (es)
CA (1) CA3119401A1 (es)
MX (1) MX2021005764A (es)
TW (1) TWI715291B (es)
UA (1) UA128703C2 (es)
WO (1) WO2020098774A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN112843007A (zh) * 2021-02-04 2021-05-28 石药集团中奇制药技术（石家庄）有限公司 一种奥拉帕利片
KR20240012437A (ko) * 2021-05-24 2024-01-29 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 질소 함유 헤테로사이클릭 화합물, 이의 제조 방법 및 의학에서 이의 응용
WO2024109871A1 (zh) * 2022-11-23 2024-05-30 江苏恒瑞医药股份有限公司 一种含氮杂环类化合物的可药用盐、晶型及制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0609386D0 (en) * 2006-05-11 2006-06-21 Active Botan Ltd Treating drug resistant cancers
CN101032464A (zh) * 2007-04-01 2007-09-12 杨喜鸿 含有利莫那班和聚乙烯吡咯烷酮的组合物、固体分散体及其制备和药物应用
EA020783B1 (ru) * 2008-10-07 2015-01-30 Астразенека Юк Лимитед Фармацевтическая композиция, содержащая 4-[3-(4-циклопропанкарбонилпиперазин-1-карбонил)-4-фторбензил]-2н-фталазин-1-он и коповидон
CN102060722B (zh) * 2009-05-01 2014-06-11 常州高新技术产业开发区三维工业技术研究所有限公司 一种含砷化合物及其制备方法和用途
JP2013537530A (ja) * 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
CN102372716A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102372698A (zh) 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102988296A (zh) * 2011-09-08 2013-03-27 江苏恒瑞医药股份有限公司 塞来昔布固体分散体及其制备方法
CN104434805B (zh) * 2013-09-22 2017-09-29 成都盛迪医药有限公司 一种替格瑞洛固体分散体及其制备方法
CN104434809B (zh) * 2014-12-10 2018-10-16 北京科莱博医药开发有限责任公司 一种奥拉帕尼固体分散体制剂及其制备方法
JP6453482B2 (ja) * 2015-03-10 2019-01-16 シオノギ インク． 固体分散体
CN106265580B (zh) * 2015-05-18 2020-09-08 中国科学院上海药物研究所 Somcl-9112固体分散体、其制备方法及包含其的somcl-9112固体制剂

Also Published As

Publication number Publication date
AU2019379706A1 (en) 2021-06-17
WO2020098774A1 (zh) 2020-05-22
CA3119401A1 (en) 2020-05-22
US20210393626A1 (en) 2021-12-23
UA128703C2 (uk) 2024-10-02
EP3881846A1 (en) 2021-09-22
EP3881846A4 (en) 2022-08-17
CN115400087A (zh) 2022-11-29
CN115400087B (zh) 2023-10-20
CN110840845B (zh) 2022-10-21
CN110840845A (zh) 2020-02-28
TW202019934A (zh) 2020-06-01
BR112021009190A2 (pt) 2021-08-17
CN115645370A (zh) 2023-01-31
TWI715291B (zh) 2021-01-01
JP7469304B2 (ja) 2024-04-16
JP2022507562A (ja) 2022-01-18
KR20210092771A (ko) 2021-07-26

Similar Documents

Publication Publication Date Title
MX2021005764A (es) Composición farmacéutica que comprende inhibidores de poli (adenosina difosfato (adp)-ribosa) polimerasas (parp).
MY196582A (en) PD-1/PD-L1 Inhibitors
MX2019012038A (es) Composiciones que comprenden una combinacion de un anticuerpo anti gen 3 de activacion del linfocito (lag-3), un inhibidor de la trayectoria del receptor de muerte programada 1 (pd-1), y un agente inmunoterapeutico.
MX2019012187A (es) Un inmunoconjugado de interleuquina-2, un agonista de cd40 y opcionalmente un antagonista de union al eje pd-1 para uso en metodos para tratar cancer.
ZA202007678B (en) Pharmaceutical combination, composition and combination formulation containing glucokinase activator and k-atp channel blocker, preparation method thereof and use thereof
MY192084A (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
GEP20207161B (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
SG10201807625PA (en) Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
CR20200184A (es) Compuestos útiles para inhibir a cdk7
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2023008954A (es) Inhibidores de los receptores erbb.
GEP20227359B (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
SG10201811128RA (en) Ezh2 inhibitors for treating lymphoma
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
MX2016017325A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble.
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
PH12019500328A1 (en) Aza-indazole compounds for use in tendon and/or ligament injuries
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
ZA202006071B (en) Antiproliferation compounds and uses thereof
MX2020007293A (es) Compuestos desuterados, composiciones y metodos para tratar canceres asociados con la activacion etbr.
MX2021014987A (es) Composiciones farmaceuticas de liberacion modificada de huperzina y metodos para usarlas.
PH12019500327A1 (en) Indazole compounds for use in tendon and/or ligament injuries
MX2019007041A (es) Metodos y composiciones para tratar la enfermedad de parkinson.